SCM
ALXO icon

Squadron Capital Management’s ALX Oncology ALXO Stock Holding History

Squadron Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,460,000
Closed -$2.93M – 45
2026
Q1 		$2.93M Buy
+1,460,000
New +$2.78M 1.07% 25

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Squadron Capital Management's ALXO Position: Q2 2026 in Review

Squadron Capital Management sold out of ALX Oncology (ALXO) in Q2 2026, closing a stake of 1,460,000 shares — an estimated $2.93M sold.

Squadron Capital Management first reported a position in ALXO in Q1 2026 and held it in 1 quarter. The position peaked at $2.93M in Q1 2026. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Squadron Capital Management reported no remaining ALX Oncology position as of Q2 2026 after selling out during the quarter.
  • Squadron Capital Management sold 1,460,000 ALX Oncology shares in Q2 2026, an estimated $2.93M.
  • Squadron Capital Management first reported a position in ALX Oncology in Q1 2026 and held it in 1 quarter.
  • Squadron Capital Management's ALX Oncology position peaked at $2.93M in Q1 2026.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.